Marshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics, School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, Guangzhou 518060, China.
Hubei Province Key Laboratory of Molecular Imaging, Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Acc Chem Res. 2020 Sep 15;53(9):1869-1880. doi: 10.1021/acs.accounts.0c00323. Epub 2020 Aug 12.
Nanomedicine has benefited from recent advances in chemistry and biomedical engineering to produce nanoscale materials as theranostic agents. Well-designed nanomaterials may present optimal biological properties, influencing circulation, retention, and excretion for imaging and treatment of various diseases. As the understanding of nanomedicine pharmacokinetics expands continuously, efficient renal clearance of nanomedicines can significantly increase the signal-to-background ratio for precision diagnosis and lower potential toxicity for improved treatment. Studies on nanomaterial-kidney interactions have led to many novel findings on the underlying principles of nanomaterial renal clearance, targeting, and accumulation. In return, the optimized nanomedicines confer significant benefits to the detection and treatment of kidney dysfunction.In this Account, we present an overview of recent progress in the development of nanomaterials for kidney theranostics, aiming to speed up translation and expand possible applications. We start by introducing biological structures of the kidney and their influence on renal targeting, retention, and clearance. Several key factors regarding renal accumulation and excretion, including nanomaterial types, sizes, and shapes, surface charges, and chemical modifications, are identified and discussed. Next, we highlight our recent efforts investigating kidney-interacting nanomaterials and introduce representative nanomedicines for imaging and treatment of kidney diseases. Multiple renal-clearable and renal-accumulating nanomedicines were devised for kidney function imaging. By employing renal-clearable nanomedicines, including gold nanoparticles, porphyrin polymers, DNA frameworks, and polyoxometalate clusters, we were able to noninvasively evaluate split renal function in healthy and diseased mice. Further engineering of renal-accumulating nanosystems has shifted attention from renal diagnosis to precision kidney protection. Many biocompatible nanomedicines, such as DNA origami, selenium-doped carbon quantum dots, melanin nanoparticles, and black phosphorus have all played essential roles in diminishing excessive reactive oxygen species for kidney treatment and protection. Finally, we discuss the challenges and perspectives of nanomaterials for renal care, their future clinical translation, and how they may affect the current landscape of clinical practices. We believe that this Account updates our current understanding of nanomaterial-kidney interactions for further design and control of nanomedicines for specific kidney diagnosis and treatment. This timely Account will generate broad interest in integrating nanotechnology and nanomaterial-biological interaction for state-of-the-art theranostics of renal diseases.
纳米医学受益于化学和生物医学工程的最新进展,从而生产出作为治疗诊断一体化试剂的纳米级材料。精心设计的纳米材料可能具有最佳的生物学特性,影响各种疾病的成像和治疗的循环、保留和排泄。随着对纳米医学药代动力学理解的不断扩展,纳米药物的有效肾脏清除可以显著提高精准诊断的信号背景比,并降低潜在毒性以实现更好的治疗效果。对纳米材料与肾脏相互作用的研究导致了许多关于纳米材料肾脏清除、靶向和积累的基本原理的新发现。反过来,优化的纳米药物为肾功能障碍的检测和治疗带来了显著的益处。在本综述中,我们介绍了用于肾脏治疗诊断的纳米材料的最新进展,旨在加速转化并扩大可能的应用。我们首先介绍了肾脏的生物结构及其对肾脏靶向、保留和清除的影响。确定并讨论了几个关于肾脏积累和排泄的关键因素,包括纳米材料类型、尺寸和形状、表面电荷和化学修饰等。接下来,我们重点介绍了我们最近在研究与肾脏相互作用的纳米材料方面的工作,并介绍了用于肾脏疾病成像和治疗的代表性纳米药物。设计了多种可肾脏清除和肾脏积累的纳米药物用于肾脏功能成像。通过使用可肾脏清除的纳米药物,包括金纳米颗粒、卟啉聚合物、DNA 框架和多金属氧酸盐簇,我们能够在健康和患病小鼠中无创评估分肾功能。进一步对肾脏积累纳米系统的工程化研究已将注意力从肾脏诊断转移到精准肾脏保护。许多生物相容性纳米药物,如 DNA 折纸、硒掺杂碳量子点、黑色素纳米颗粒和黑磷,都在减少肾脏治疗和保护中过多的活性氧方面发挥了重要作用。最后,我们讨论了用于肾脏护理的纳米材料的挑战和前景、它们的未来临床转化以及它们如何影响当前的临床实践格局。我们相信,本综述更新了我们对纳米材料与肾脏相互作用的现有理解,有助于进一步设计和控制用于特定肾脏诊断和治疗的纳米药物。本综述将为整合纳米技术和纳米材料-生物相互作用以实现肾脏疾病的最新治疗诊断一体化技术提供广泛的兴趣。
Acc Chem Res. 2020-9-15
Macromol Rapid Commun. 2020-9
Nat Rev Nephrol. 2016-10-31
Kidney Int. 2016-10
Nat Rev Nephrol. 2024-6
Angew Chem Int Ed Engl. 2017-12-5
Curr Top Med Chem. 2013
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015-4-6
Int J Nanomedicine. 2025-2-5
J Am Soc Nephrol. 2025-3-1
Signal Transduct Target Ther. 2024-8-12
Nanomaterials (Basel). 2024-6-25
J Nanobiotechnology. 2024-7-4
Proc Natl Acad Sci U S A. 2024-6-4
ACS Appl Bio Mater. 2024-12-16
J Control Release. 2020-6-10
Adv Funct Mater. 2019-11-28
Nano Lett. 2020-2-12
Angew Chem Int Ed Engl. 2020-3-9
Angew Chem Int Ed Engl. 2019-10-24
Nat Nanotechnol. 2019-9-2
Angew Chem Int Ed Engl. 2019-9-5